{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:44:33Z","timestamp":1781538273371,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41401-020-0420-8","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T14:13:29Z","timestamp":1589811209000},"page":"1457-1464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["MG53 protects against contrast-induced acute kidney injury by reducing cell membrane damage and apoptosis"],"prefix":"10.1038","volume":"41","author":[{"given":"Chao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-qun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo-fen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-mei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-hui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-chang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad H.","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,18]]},"reference":[{"key":"420_CR1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrneph.2010.116","volume":"6","author":"AD Calvin","year":"2010","unstructured":"Calvin AD, Misra S, Pflueger A. Contrast-induced acute kidney injury and diabetic nephropathy. Nat Rev Nephrol. 2010;6:679\u201388.","journal-title":"Nat Rev Nephrol"},{"key":"420_CR2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/0003-4819-110-2-119","volume":"110","author":"CJ Davidson","year":"1989","unstructured":"Davidson CJ, Hlatky M, Morris KG, Pieper K, Skelton TN, Schwab SJ, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med. 1989;110:119\u201324.","journal-title":"Ann Intern Med"},{"key":"420_CR3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jacc.2007.12.035","volume":"51","author":"PA McCullough","year":"2008","unstructured":"McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51:1419\u201328.","journal-title":"J Am Coll Cardiol"},{"key":"420_CR4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrneph.2016.196","volume":"13","author":"M F\u00e4hling","year":"2017","unstructured":"F\u00e4hling M, Seeliger E, Patzak A, Persson PB. Understanding and preventing contrast-induced acute kidney injury. Nat Rev Nephrol. 2017;13:169\u201380.","journal-title":"Nat Rev Nephrol"},{"key":"420_CR5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1681\/ASN.V111177","volume":"11","author":"SW Murphy","year":"2000","unstructured":"Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol. 2000;11:177\u201382.","journal-title":"J Am Soc Nephrol"},{"key":"420_CR6","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jacc.2004.06.075","volume":"44","author":"M Maeder","year":"2004","unstructured":"Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol. 2004;44:1763\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"420_CR7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ejvs.2015.12.013","volume":"51","author":"ZS Rancic","year":"2016","unstructured":"Rancic ZS. Commentary on 'Contrast Induced Nephropathy and Long-term Renal Decline After Percutaneous Transluminal Angioplasty for Symptomatic Peripheral Arterial Disease'. Eur J Vasc Endovasc Surg. 2016;51:394.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"420_CR8","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1161\/CIRCULATIONAHA.105.595090","volume":"113","author":"M Tepel","year":"2006","unstructured":"Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113:1799\u2013806.","journal-title":"Circulation."},{"key":"420_CR9","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/eurheartj\/ehr494","volume":"33","author":"E Seeliger","year":"2012","unstructured":"Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33:2007\u201315.","journal-title":"Eur Heart J."},{"key":"420_CR10","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/eurheartj\/ehu126","volume":"35","author":"J Silvain","year":"2014","unstructured":"Silvain J, Collet JP, Montalescot G. Contrast-induced nephropathy: the sin of primary percutaneous coronary intervention? Eur Heart J. 2014;35:1504\u20136.","journal-title":"Eur Heart J"},{"key":"420_CR11","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehn197","volume":"29","author":"G Romano","year":"2008","unstructured":"Romano G, Briguori C, Quintavalle C, Zanca C, Rivera NV, Colombo A, et al. Contrast agents and renal cell apoptosis. Eur Heart J. 2008;29:2569\u201376.","journal-title":"Eur Heart J"},{"key":"420_CR12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pharmthera.2017.06.009","volume":"180","author":"C Mamoulakis","year":"2017","unstructured":"Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, et al. Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther. 2017;180:99\u2013112.","journal-title":"Pharmacol Ther."},{"key":"420_CR13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/bmj.38943.401852.80","volume":"333","author":"R Mathew","year":"2006","unstructured":"Mathew R, Haque K, Woothipoom W. Acute renal failure induced by contrast medium: steps towards prevention. BMJ. 2006;333:539\u201340.","journal-title":"BMJ."},{"key":"420_CR14","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/CIRCULATIONAHA.111.038943","volume":"124","author":"ACT Investigators","year":"2011","unstructured":"ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124:1250\u20139.","journal-title":"Circulation."},{"key":"420_CR15","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jacc.2009.08.091","volume":"55","author":"H Thiele","year":"2010","unstructured":"Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol. 2010;55:2201\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"420_CR16","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1056\/NEJMoa054209","volume":"354","author":"G Marenzi","year":"2006","unstructured":"Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773\u201382.","journal-title":"N Engl J Med"},{"key":"420_CR17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-148-4-200802190-00007","volume":"148","author":"AM Kelly","year":"2008","unstructured":"Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148:284\u201394.","journal-title":"Ann Intern Med"},{"key":"420_CR18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2011.128","volume":"7","author":"H Myrvang","year":"2011","unstructured":"Myrvang H. Acute kidney injury: Acetylcysteine does not prevent contrast-induced acute kidney injury. Nat Rev Nephrol. 2011;7:605.","journal-title":"Nat Rev Nephrol"},{"key":"420_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/cr.2017.133","volume":"28","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Chen X, Gueydan C, Han J. Plasma membrane changes during programmed cell deaths. Cell Res. 2018;28:9\u201321.","journal-title":"Cell Res."},{"key":"420_CR20","doi-asserted-by":"crossref","first-page":"1247136","DOI":"10.1126\/science.1247136","volume":"343","author":"AJ Jimenez","year":"2014","unstructured":"Jimenez AJ, Maiuri P, Lafaurie-Janvore J, Divoux S, Piel M, Perez F. ESCRT machinery is required for plasma membrane repair. Science. 2014;343:1247136.","journal-title":"Science."},{"key":"420_CR21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1440-1681.2011.05503.x","volume":"38","author":"MM Sendeski","year":"2011","unstructured":"Sendeski MM. Pathophysiology of renal tissue damage by iodinated contrast media. Clin Exp Pharmacol Physiol. 2011;38:292\u20139.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"420_CR22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ncb1812","volume":"11","author":"C Cai","year":"2009","unstructured":"Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, et al. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol. 2009;11:56\u201364.","journal-title":"Nat Cell Biol"},{"key":"420_CR23","volume":"4","author":"JS Yi","year":"2013","unstructured":"Yi JS, Park JS, Ham YM, Nguyen N, Lee NR, Hong J, et al. MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling. Nat Commun. 2013;4:2354.","journal-title":"Nat Commun."},{"key":"420_CR24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.5483\/BMBRep.2016.49.8.079","volume":"49","author":"T Tan","year":"2016","unstructured":"Tan T, Ko YG, Ma J. Dual function of MG53 in membrane repair and insulin signaling. BMB Rep. 2016;49:414\u201323.","journal-title":"BMB Rep."},{"key":"420_CR25","doi-asserted-by":"crossref","first-page":"139ra85","DOI":"10.1126\/scitranslmed.3003921","volume":"4","author":"N Weisleder","year":"2012","unstructured":"Weisleder N, Takizawa N, Lin P, Wang X, Cao C, Zhang Y, et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med. 2012;4:139ra85.","journal-title":"Sci Transl Med"},{"key":"420_CR26","volume":"5","author":"Y Jia","year":"2014","unstructured":"Jia Y, Chen K, Lin P, Lieber G, Nishi M, Yan R, et al. Treatment of acute lung injury by targeting MG53-mediated cell membrane repair. Nat Commun. 2014;5:4387.","journal-title":"Nat Commun."},{"key":"420_CR27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yjmcc.2014.12.010","volume":"80","author":"J Liu","year":"2015","unstructured":"Liu J, Zhu H, Zheng Y, Xu Z, Li L, Tan T, et al. Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury. J Mol Cell Cardiol. 2015;80:10\u20139.","journal-title":"J Mol Cell Cardiol"},{"key":"420_CR28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s42003-019-0316-7","volume":"2","author":"HL Chandler","year":"2019","unstructured":"Chandler HL, Tan T, Yang C, Gemensky-Metzler AJ, Wehrman RF, Jiang Q, et al. MG53 promotes corneal wound healing and mitigates fibrotic remodeling in rodents. Commun Biol. 2019;2:71.","journal-title":"Commun Biol."},{"key":"420_CR29","doi-asserted-by":"crossref","first-page":"279ra36","DOI":"10.1126\/scitranslmed.3010755","volume":"7","author":"D Pu","year":"2015","unstructured":"Pu D, Li H, Lin P, Tan T, Wang Z, Chen K, et al. MG53-mediated cell membrane repair protects against acute kidney injury. Sci Transl Med. 2015;7:279ra36.","journal-title":"Sci Transl Med"},{"key":"420_CR30","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1172\/JCI117421","volume":"94","author":"Y Agmon","year":"1994","unstructured":"Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest. 1994;94:1069\u201375.","journal-title":"J Clin Invest"},{"key":"420_CR31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1681\/ASN.2007040481","volume":"19","author":"Y Yokomaku","year":"2008","unstructured":"Yokomaku Y, Sugimoto T, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, et al. Asialoerythropoietin prevents contrast-induced nephropathy. J Am Soc Nephrol. 2008;19:321\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"420_CR32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/jcm8020147","volume":"8","author":"YH Chen","year":"2019","unstructured":"Chen YH, Fu YC, Wu MJ. Does Resveratrol Play a Role in Decreasing the Inflammation Associated with Contrast Induced Nephropathy in Rat Model? J Clin Med. 2019;8:147.","journal-title":"J Clin Med"},{"key":"420_CR33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2013.08.038","volume":"718","author":"Z Wang","year":"2013","unstructured":"Wang Z, Liu Y, Han Y, Guan W, Kou X, Fu J, et al. Protective effects of aliskiren on ischemia\u2013reperfusion-induced renal injury in rats. Eur J Pharmacol. 2013;718:160\u20136.","journal-title":"Eur J Pharmacol"},{"key":"420_CR34","doi-asserted-by":"crossref","first-page":"24592","DOI":"10.1074\/jbc.M115.680074","volume":"290","author":"H Li","year":"2015","unstructured":"Li H, Duann P, Lin PH, Zhao L, Fan Z, Tan T, et al. Modulation of wound healing and scar formation by MG53 protein-mediated cell membrane repair. J Biol Chem. 2015;290:24592\u2013603.","journal-title":"J Biol Chem"},{"key":"420_CR35","doi-asserted-by":"crossref","first-page":"22474","DOI":"10.18632\/oncotarget.7965","volume":"7","author":"Y Yao","year":"2016","unstructured":"Yao Y, Zhang B, Zhu H, Li H, Han Y, Chen K, et al. MG53 permeates through blood-brain barrier to protect ischemic brain injury. Oncotarget. 2016;7:22474\u201385.","journal-title":"Oncotarget."},{"key":"420_CR36","first-page":"2717","volume":"52","author":"N Weisleder","year":"2011","unstructured":"Weisleder N, Lin P, Zhao X, Orange M, Zhu H, Ma J. Visualization of MG53-mediated cell membrane repair using in vivo and in vitro systems. J Vis Exp. 2011;52:2717.","journal-title":"J Vis Exp"},{"key":"420_CR37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4161\/cib.2.3.8077","volume":"2","author":"N Weisleder","year":"2009","unstructured":"Weisleder N, Takeshima H, Ma J. Mitsugumin 53 (MG53) facilitates vesicle trafficking in striated muscle to contribute to cell membrane repair. Commun Integr Biol. 2009;2:225\u20136.","journal-title":"Commun Integr Biol"},{"key":"420_CR38","doi-asserted-by":"crossref","first-page":"15894","DOI":"10.1074\/jbc.M109.009589","volume":"284","author":"C Cai","year":"2009","unstructured":"Cai C, Weisleder N, Ko JK, Komazaki S, Sunada Y, Nishi M, et al. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem. 2009;284:15894\u2013902.","journal-title":"J Biol Chem"},{"key":"420_CR39","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/cvr\/cvr029","volume":"91","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Lv F, Jin L, Peng W, Song R, Ma J, et al. MG53 participates in ischaemic postconditioning through the RISK signalling pathway. Cardiovasc Res. 2011;91:108\u201315.","journal-title":"Cardiovasc Res"},{"key":"420_CR40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/2321-3868.123074","volume":"1","author":"Y Wu","year":"2013","unstructured":"Wu Y, Huang J, Liu D, Tan J, Peng Y, Yang J, et al. Mitsugumin 53 protects the kidney from severe burn injury in mice. Burns Trauma. 2013;1:128\u201333.","journal-title":"Burns Trauma."},{"key":"420_CR41","doi-asserted-by":"crossref","first-page":"249810","DOI":"10.1155\/2014\/249810","volume":"2014","author":"A Michael","year":"2014","unstructured":"Michael A, Faga T, Pisani A, Riccio E, Bramanti P, Sabbatini M, et al. Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast media. Biomed Res Int. 2014;2014:249810.","journal-title":"Biomed Res Int"},{"key":"420_CR42","doi-asserted-by":"crossref","first-page":"F864","DOI":"10.1152\/ajprenal.00302.2013","volume":"306","author":"ZZ Liu","year":"2014","unstructured":"Liu ZZ, Schmerbach K, Lu Y, Perlewitz A, Nikitina T, Cantow K, et al. Iodinated contrast media cause direct tubular cell damage, leading to oxidative stress, low nitric oxide, and impairment of tubuloglomerular feedback. Am J Physiol Renal Physiol. 2014;306:F864\u201372.","journal-title":"Am J Physiol Renal Physiol"},{"key":"420_CR43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1523-1755.2003.00059.x","volume":"64","author":"RA Zager","year":"2003","unstructured":"Zager RA, Johnson ACM, Hanson SY. Radiographic contrast media-induced tubular injury: Evaluation of oxidant stress and plasma membrane integrity. Kidney Int. 2003;64:128\u201339.","journal-title":"Kidney Int."},{"key":"420_CR44","doi-asserted-by":"crossref","first-page":"12820","DOI":"10.1074\/jbc.C111.221440","volume":"286","author":"H Zhu","year":"2011","unstructured":"Zhu H, Lin P, De G, Choi KH, Takeshima H, Weisleder N, et al. Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair. J Biol Chem. 2011;286:12820\u20134.","journal-title":"J Biol Chem"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0420-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:25Z","timestamp":1684616605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-0420-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,18]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["420"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-0420-8","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,18]]},"assertion":[{"value":"15 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JJM and TT have an equity interest in TRIM-edicine, Inc., which develops rhMG53 for the treatment of human diseases. Patents on the use of MG53 are held by Rutgers University\u2014Robert Wood Johnson Medical School.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}